Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology

Bioptimus Strengthens Commercial and Scientific Leadership with Key Hires

Introducing Latent-X, a frontier generative AI model for protein binder design accessible via no-code platform for push-button protein design

Bioptimus appoints Julie Gerardi as Chief Commercial Officer

Latent Labs and AWS announce collaboration to scale generative AI for the Life Sciences

Latent Labs secures $50M in funding to realize the potential of AI-powered, programmable biology

Digital Medicine

Betteromics

BioCorteX

Bioptimus

Cure51

deepc

Kiro 

L'école AI

Latent Labs

The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.

Edward Kliphuis

Simon Turner

Edward is a Partner in the Sofinnova Digital Medicine Strategy. He joined us in 2021 from M Ventures, Merck KGaA’s corporate VC arm, where he focused on investments in cutting-edge digital medicine companies, including developers of the first FDA-approved videogame therapy.

Before that, Edward was in the Life Sciences securities team at Kempen & Co, a pan-European merchant bank, covering listed small- and mid-cap life sciences equities. He started his career as an analyst within the biopharma investment team of M Ventures.

Edward is positive, energetic and purpose-driven — and he enjoys a challenge. In 2012, for instance, he took on the Gobi Desert in an underpowered 1.2L Chevrolet Aveo, which he and his team drove from London to Mongolia to raise money for SOS Children's Villages.

He holds an M.Sc. in Biopharmaceutical Sciences from Leiden University, The Netherlands, with a specialization in pharmacology.

Simon is a Partner in the Sofinnova Digital Medicine Strategy. He joined us in 2021 after consulting for corporates seeking to develop partnerships with digital health companies. He worked closely with business development functions to identify, assess, and structure strategic investments.

Prior to that, Simon was at Baxter International, where he was part of the External Innovation Department. He has worked with various innovation agencies and chaired financing panels.

Simon enjoys constant exposure to novel technologies, curious and motivated people, and supporting the development of companies that are striving to improve medicine. He decided to join Sofinnova because of the strong team spirit and collective drive.

He has a BSc in Biomedical Science from King’s College London and an MSc in International Business from SKEMA Business School.

Javier is a Principal with the Sofinnova Digital Medicine Strategy. He is a thesis-driven VC Investor at the intersection of healthcare and technology, with a variety of experience in different European healthcare systems.

He came to Sofinnova Partners from Heal Capital, a €100 million early-stage HealthTech venture capital fund where he was the first employee and where he played an active role in the growth of the fund from zero to 12 investments. Before that, he was an Analyst at the New Businesses Fund at M Ventures, working on investments in data-driven healthcare, biotechnology and automation.

Javier was a practicing clinical doctor at Oxford University Hospital Trust in the UK. He has held posts at Britain’s National Spinal Injury Centre and Oxford’s Churchill Hospital Transplant Department, the largest pancreatic transplant center in Europe.

Javier holds an MPhil (distinction) from Cambridge University and completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Newcastle University.

Aishu is an Analyst with the Sofinnova Digital Medicine Strategy. She joined us in 2023 after completing a stint as a full-time Investment Fellow at BioGeneration Ventures.

Her ten-year academic career weaved together neuroscience, engineering, and computation across Asia, Europe, and the U.S. Aishu says her transition into venture capital was "sparked by a genuine eagerness to learn about and support advancements at the confluence of scientific exploration and computation."

Aishu holds a PhD from the National University of Singapore, and an MS in Electrical and Computer Engineering and Computational Neuroscience from the University of Florida.

Her PhD work was published in journals including Nature Neuroscience and Nature Communications. Other fellowships she was awarded include Horizon 2020's Marie Curie Fellowship and a full-time fellowship at the Netherlands Institute for Neuroscience, where she studied the activity of neurons in the prefrontal cortex, using machine learning and AI to understand how rodent neurons work together to arrive at a decision using environmental cues.

TheTeam